Therapy News and Research

RSS

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

First field study shows lack of exposure to morning light delays sleep in teenagers

The first field study on the impact of light on teenagers' sleeping habits finds that insufficient daily morning light exposure contributes to teenagers not getting enough sleep.

17 Feb 2010

High-fat ketogenic diet safe and effective for controlling childhood seizures

Current and former patients treated with the high-fat ketogenic diet to control multiple, daily and severe seizures can be reassured by the news that not only is the diet effective, but it also appears to have no long-lasting side effects, say scientists at Johns Hopkins Children's Center.

17 Feb 2010

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.

17 Feb 2010

Right-ventricular impairment increases risk of death in heart-failure patients

New research from the University of Alabama at Birmingham (UAB) suggests that the ability of right side of the heart to pump blood may be an indication of the risk of death to heart-failure patients whose condition is caused by low function by the left side of their heart.

17 Feb 2010

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two-thirds of today's cancer patients.

17 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

New research report on orthopedic biomaterials market in the U.S.

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for orthopedic biomaterials grew by 11.5% in 2009 and is estimated to reach almost $6.3 billion by 2016.

17 Feb 2010

Study shows value-based plans can improve adherence for diabetes medicines

A study by CVS Caremark (NYSE: CVS), published this week in the American Journal of Pharmacy Benefits, finds that insurance benefit designs that reduce the cost of medications for plan participants result in patients being more likely to start and stay on their medication therapy.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.

16 Feb 2010

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

EVOLVE WELLNESS CENTER expands to prominent new space in West Hollywood

EVOLVE WELLNESS CENTER, Los Angeles’ premier Acupuncture group for more than 13 years has expanded to a prominent new space in West Hollywood and is planning to celebrate its Grand Re-Opening with a great deal of fanfare.

16 Feb 2010

SEGT helpful for breast cancer patients with affective disorders

A pilot investigation performed by a group of Italian investigators and published in the current issue of Psychotherapy and Psychosomatics indicates that supportive-expressive group therapy is helpful in patients with breast cancer.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Aegis Living opens new senior living community in Bellevue

The heart of Bellevue now boasts a new senior living community that is perfectly suited to the needs and desires for residents of the Eastside. Aegis Living, a national leader in senior, assisted living and memory care communities, recently opened its 34th community to a crowd of hundreds, as new and prospective residents and families came to celebrate the grand opening event.

16 Feb 2010

Therapy News and Research

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

First field study shows lack of exposure to morning light delays sleep in teenagers

High-fat ketogenic diet safe and effective for controlling childhood seizures

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

Right-ventricular impairment increases risk of death in heart-failure patients

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

Generx clinical development opportunities: bioRASI to assist Cardium

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

New research report on orthopedic biomaterials market in the U.S.

Study shows value-based plans can improve adherence for diabetes medicines

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Special issue reviews current state of science in fetal therapy

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

Merck announces global sales of $27.4 billion for full-year 2009

EVOLVE WELLNESS CENTER expands to prominent new space in West Hollywood

SEGT helpful for breast cancer patients with affective disorders

Meda publishes 2009 year-end report

Aegis Living opens new senior living community in Bellevue

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News